This review describes strategies for producing castrate levels of testosterone in men with androgen-sensitive prostate cancer (PC) and the associated toxicities, with particular focus on the re-emergence and potential benefits of parenteral estrogen. In the developed world, PC is the commonest malignancy and second commonest cause of cancer death affecting men. Its incidence is increasing with an aging population and frequent prostate-specific antigen (PSA) testing.
in the 1980s for ADT. Unlike the pulsatile action of hypothalamic LHRH, synthetic LHRHa continually stimulate pituitary receptors, causing downregulation of the receptors and central hypogonadism.
Initial exposure to LHRHa leads to a surge in androgen production, termed 'testosterone flare', which in some patients can exacerbate symptoms, such as bone pain from skeletal metastasis, increase the risk for aggravating nerve compression (e.g. spinal cord compression), or worsen urinary outflow obstruction. Short courses of anti-androgens that compete with androgens for receptor binding are given to avoid these complications. 7, 8 ADT with LHRHa is a mainstay of contemporary PC treatment. It is used alone to control PC or in the neoadjuvant/adjuvant setting with radical surgery or radiotherapy. It is also used for advanced PC, which can be incurable at presentation or as a result of disease recurrence following the failure of radical therapy. Estimates suggest that more than half of the men diagnosed with PC will be treated with ADT at some point during the course of their disease, remaining on it for a decade or even more. 9 
Novel Agents
Degarelix, an LHRH antagonist, is another form of ADT that binds competitively to pituitary LHRH receptors. 10 It reduces LH and testosterone levels without causing testosterone flare. Other newer agents include abiraterone (an inhibitor of androgen biosynthesis) and enzalutamide (an inhibitor of nuclear translocation of the androgen receptor) that are currently reserved for use in castration-resistant PC, when the cancer no longer responds to ADT despite castrate levels of testosterone.
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Toxicities of Androgen Deprivation Therapy
In the last decade there has been a growing recognition of the need to understand the nature and impact of the toxicities from contemporary ADT with LHRHa. This becomes more salient when considering the everincreasing and widespread use of LHRHa, as the incidence of PC and overall survival with PC increases. LHRHa toxicity has a large impact on the health economy and overall cost of treating PC. LHRHa are associated with multiple adverse effects (see Figure 1 ) including osteoporosis and associated fractures, hot flashes, imbalances in lipid and glucose homeostasis, diminished libido, erectile dysfunction, depression, cognitive decline, loss of musculature, adiposity, anemia, increased susceptibility to CVS events, and decreased physical strength. [11] [12] [13] [14] [15] [16] [17] [18] [19] Some toxicities of LHRHa can be attributed to low testosterone levels.
These include loss of libido, erectile dysfunction, and low muscle mass. Others, such as osteoporosis, fracture risk, hot flashes, and dyslipidemia are thought to be due to the accompanying estrogen deficiency (80 % reduction in estrogen levels by LHRHa), as testosterone is required for synthesis of estrogen through aromatization. [19] [20] [21] Collectively these toxicities are labeled as 'castration syndrome' or 'androgen deprivation syndrome,' and greatly impact upon quality of life (QoL). ADT also affects the intimate partners of those receiving ADT and studies suggest that partners often experience more distress than the patients themselves. 22 A recent study in healthy individuals without PC has attempted to identify which short-term metabolic effects of ADT are related to testosterone insufficiency and which are related to estrogen insufficiency. 23 The study enrolled 400 patients, divided into two equal cohorts (198 patients in cohort 1; 202 patients in cohort 2). Patients in both cohorts received a LHRHa (goserelin) and were then randomized to varying levels of testosterone replacement (0, 1.25 g, 2.5g, 5 g, and 10 g of testosterone gel in 24 hours). The second cohort additionally received anastrazole (which prevents the aromatization of testosterone to estrogen). Thus, in cohort 1 the varying levels of testosterone replacement were physiologically converted into estrogen, whereas in cohort 2 estrogen levels were suppressed with anastrazole, irrespective of the level of testosterone replacement. The study showed that testosterone deficiency led to a decrease in lean body mass, muscle mass, and muscle strength. The dose of testosterone to avoid these adverse effects was wide ranging among both cohorts. Estrogen deficiency seen in cohort 2 accounted for increases in percentage body fat. Increased deposition of body fat is thought to be associated with decreased insulin sensitivity and an increased risk for diabetes. 24 Both groups showed a decrease in sexual desire and function.
Bone Weakness
There is extensive evidence showing the detrimental effect of ADT with LHRHa on bone health. 25 LHRHa decreases bone mineral density and promotes bone turnover 26 and has been shown to increase fracture risk by two to four times with the resulting fractures associated with increased mortality and decreased QoL. 27 A recent study utilizing the Surveillance, Epidemiology and End Results (SEER) -Medicare database of 76,000 men with localized PC showed that men with a high baseline risk for skeletal complications had a higher probability of receiving ADT than those with a low risk (52.1 % versus 38.2 %; p<0.001).
Those more likely to receive ADT in this study were older men, with 
Vasomotor Symptoms and Sleep Disturbance
Vasomotor symptoms, such as hot flashes and night sweats, are common, affecting almost four out of every five patients receiving ADT. They are thought to be caused by changes in sex hormone levels (particularly estrogen), which disrupt the negative feedback of hypothalamic noradrenaline production leading to a resetting of the thalamic thermoregulatory mechanism. [29] [30] [31] [32] Hot flashes appear shortly after LHRHa administration, do not appear to subside with the end of treatment, and are associated with substantial psychological distress. 21 Disturbance of sleep is also a common occurrence in patients treated for PC. A recent questionnaire-based study showed higher insomnia scores in patients receiving ADT with radiotherapy compared with radiotherapy alone.
Hot flashes and night sweats appear to contribute to this sleep disturbance.
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Cognitive Impairment in ADT users (type of ADT not specified) over a period of 1 year. 37 Functional imaging studies are being used to investigate this further. Reduced activation in the parieto-occipital lobe on a mental rotation task (a test of visuospatial memory) with ADT was seen with functional magnetic resonance imaging (fMRI). 38 A similar study showed reduced pre-frontal activation on fMRI, but no cognitive deficit, 39 and a further study showed decreased cortical gray matter volume in ADT users. 40 
Sexual Inactivity and Spousal Relations
Sexual activity has been shown to decline considerably in PC patients on ADT with up to 85 % of the patients reporting sexual side effects. 12, 31, 41, 42 This sexual inactivity is a consequence of diminished libido, physical changes (decreased strength, adiposity, genital shrinkage), and erectile dysfunction. 12, 43 Loss of masculine traits in PC patients negatively impacts their psychosocial and sexual life. 42 In one small study (n=15), nearly half the men on ADT experienced an erosion of spousal relations. 44 This may be related to a degree of estrogen deficiency, as estrogen replacement appears to alleviate some of these symptoms. 45 
Changes in Body Composition and Physical Function
Body composition changes considerably in men undergoing ADT with LHRHa therapy, with more extensive changes seen with a longer duration of treatment. These changes include increased fat mass (adiposity), loss of lean musculature (sarcopenia), and weight gain. 11, 46 Smith et al.
prospectively measured lean body mass at three time points following the start of ADT and compared it with baseline measurements. A significant decline in mean lean body mass was seen at 1 year (1 % decrease; p<0.01), 2 years (2.1 % decrease; p<0.001), and 3 years (2.4 % decrease; p<0.001). 47 Fatigue affects nearly half of the patients on ADT and decreased muscle mass and increased adiposity may be important factors contributing to this. 18 Endurance, upper extremity strength, and physical activity are affected within 3 months of starting ADT. 
Metabolic Disturbances and Cardiovascular Risks
The relationship between CVS risk and LHRHa therapy appears complex.
Treatment with LHRHa has been linked to hyperglycemia, insulin resistance, dyslipidemia, and the development of the metabolic syndrome suggesting an increased risk for diabetes and CVS disease in these patients. 11, 32 Observational data from Medicare databases suggest that men receiving the highest rates are seen with estrogen (more than 50 % men affected).
Rates are similar with surgical orchiectomy and LHRHa (10-15 %).
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Parenteral Estrogen as Androgen Deprivation Therapy
The route of administration of estrogen is thought to explain the CVS toxicity seen with the oral preparations. When estrogen is taken orally, enterohepatic first pass exposes the liver to high levels of estrogen resulting in upregulation of pro-coagulant proteins (increased clotting factors I, II, VII, IX, and X) and downregulation of anti-coagulant factors (decreased plasminogen activator and anti-thrombin III). This estrogen-induced hypercoaguable state in turn increases the risk for thromboembolic and CVS events. study (see Figure 2 ). PATCH is a large phase II randomized clinical trial comparing transdermal estrogen patches with LHRHa in locally advanced and metastatic PC. In a cohort of 254 men (randomized 2:1 to patches or LHRHa) with a median follow-up of 19 months, the rates of CVS events (the primary outcome measure) were similar in the two trial arms (see Table 1 ). Testosterone suppression rates were also similar in the two groups. 58 An extension to this trial is ongoing and has recruited to date nearly 700 men (excluding the first 50 randomized before the initial patch dose regime change) and will provide further efficacy and toxicity data. Proportion ( 
CI = confidence interval. *The primary cardiovascular analysis was based on a modified intention-to-treat approach: patients were included in the estrogen patch group if they had been treated with patches at any point, and were included in the luteinizing hormone-releasing hormone agonist (LHRHa) group if they had received LHRH but not patches at any point. Median follow-up was 19 months (interquartile range 12-31). The analysis was not powered to compare treatment groups. $ Based on patients with data available who are still on allocated treatment without additional therapy. Reproduced from Langley et al. 58
Potential Benefits of Androgen Deprivation Therapy with Parenteral Estrogen
Exogenous parenteral estrogen for ADT potentially offers two major therapeutic benefits. First, it appears to circumvent the CVS toxicity of oral estrogen by avoiding hepatic first-pass metabolism. 56 Second, exogenous estrogen replaces endogenous estrogen, which would be lost through LHRHa administration. 58 Thus exogenous estrogen as a single agent has the potential of being an effective and cost-effective therapy for PC, avoiding the need for further expensive treatment of conditions caused by LHRHa.
Bone Health
Estrogen preserves bone mass through its anti-resorptive actions mediated by estrogen receptors. It is known to inhibit osteoclastogenesis and increase osteoclast apoptosis. The life span of bone-resorptive osteoclasts is prolonged in estrogen deficiency, and the resultant imbalance between the bone-forming osteoblasts and osteoclasts increases the rate of bone thinning and heightens the risk for fracture.
The protective effects of estrogen in bone health have been studied extensively in the context of the female menopause. 59 In 
Metabolic Profile
It has been suggested that estrogen has a role in the protection from atherosclerosis as rates of CVS disease in premenopausal women are lower compared with men of the same age. Data from the nurses health study including over 29,000 women, also suggested early menopause increases the risk for CVS disease. 63 In post-menopausal women CVS disease rates increase to attain similar rates as men of the same age. However, randomized data have not confirmed this association and HRT in postmenopausal women is not recommended for this indication. 64 Beneficial arterial effects of estrogen may be mediated through an improved lipid profile as there is evidence that estrogen reduces low-density lipoprotein (LDL) and increases high-density lipoprotein (HDL). 65 Similar favorable lipid changes have been observed with the use of parenteral estrogen as ADT for PC (see Table 1 ). 21 Results from the PATCH trial showed that at 6 and 12 months, mean fasting cholesterol increased in the LHRHa arm but decreased in the estrogen arm, whereas HDL increased in both. Mean fasting glucose increased in the LHRHa group at 6 months and again further at 12 months but showed a decrease in the estrogen group at 6 months, which was maintained unchanged at 12 months. Whether these effects on exogenous hormones impact directly on cardiac risk is unclear, both for HRT and ADT.
Hot Flashes
Several studies have highlighted the role of estrogen in preventing and treating hot flashes. 21 In one such study, a significant decline in hot flashes (77 % reduction; p<0.02) after 8 weeks in men receiving transdermal estradiol as second-line therapy for castration-resistant PC was observed.
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Conclusion
Long-term ADT is becoming increasingly common as men live longer with a diagnosis of PC. By creating both testosterone and estrogen deficiency, contemporary ADT with LHRHa causes a range of significant side effects.
The large number of patients receiving LHRHa greatly amplifies the impact of this toxicity and have been under-estimated in the literature. 67 The wide-ranging nature of these effects complicates discussion in clinical practice 68 particularly if patients are older with multiple comorbidities. 
